Literature DB >> 23891187

Selective orexin receptor antagonists.

Terry P Lebold1, Pascal Bonaventure, Brock T Shireman.   

Abstract

The orexin, or hypocretin, neuropeptides (orexin-A and orexin-B) are produced on neurons in the hypothalamus which project to key areas of the brain that control sleep-wake states, modulation of food intake, panic, anxiety, emotion, reward and addictive behaviors. These neuropeptides exert their effects on a pair of G-protein coupled receptors termed the orexin-1 (OX1) and orexin-2 (OX2) receptors. Emerging biology suggests the involvement of these receptors in psychiatric disorders as they are thought to play a key role in the regulation of multiple systems. This review is intended to highlight key selective OX1 or OX2 small-molecule antagonists.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hcrt-1; Hcrt-2; Hypocretin; Hypothalamus; Orexin

Mesh:

Substances:

Year:  2013        PMID: 23891187     DOI: 10.1016/j.bmcl.2013.06.057

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  The effect of orexin B on steroidogenic acute regulatory protein, P450 side-chain cleavage enzyme, and 3β-hydroxysteroid dehydrogenase gene expression, and progesterone and androstenedione secretion by the porcine uterus during early pregnancy and the estrous cycle.

Authors:  Katarzyna Kisielewska; Edyta Rytelewska; Marlena Gudelska; Marta Kiezun; Kamil Dobrzyn; Karol Szeszko; Kinga Bors; Joanna Wyrebek; Tadeusz Kaminski; Nina Smolinska
Journal:  J Anim Sci       Date:  2019-02-01       Impact factor: 3.159

2.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

3.  Structure-based development of a subtype-selective orexin 1 receptor antagonist.

Authors:  Jan Hellmann; Matthäus Drabek; Jie Yin; Jakub Gunera; Theresa Pröll; Frank Kraus; Christopher J Langmead; Harald Hübner; Dorothee Weikert; Peter Kolb; Daniel M Rosenbaum; Peter Gmeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

4.  Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling.

Authors:  K A Levy; Z D Brodnik; J K Shaw; D A Perrey; Y Zhang; R A España
Journal:  Psychopharmacology (Berl)       Date:  2017-06-30       Impact factor: 4.530

5.  Hypocretin/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine.

Authors:  Jessica K Shaw; Mark J Ferris; Jason L Locke; Zachary D Brodnik; Sara R Jones; Rodrigo A España
Journal:  Addict Biol       Date:  2016-08-02       Impact factor: 4.280

6.  Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.

Authors:  David A Perrey; Ann M Decker; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2017-11-20       Impact factor: 4.418

Review 7.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

8.  The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.

Authors:  David A Perrey; Ann M Decker; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  Bioorg Med Chem       Date:  2015-07-16       Impact factor: 3.641

9.  OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES.

Authors:  Philip L Johnson; Lauren M Federici; Stephanie D Fitz; John J Renger; Brock Shireman; Christopher J Winrow; Pascal Bonaventure; Anantha Shekhar
Journal:  Depress Anxiety       Date:  2015-08-19       Impact factor: 6.505

10.  Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine.

Authors:  David L Bernstein; Preeti S Badve; Jessica R Barson; Caroline E Bass; Rodrigo A España
Journal:  Addict Biol       Date:  2017-10-02       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.